Article
AIM & Small Cap Medtech & Diagnostics genedrive

Genedrive Chairman Ian Gilham steps down as board rebuild continues

Dr. Ian Gilham has left the Genedrive board as the point-of-care pharmacogenetic testing company searches for a new independent Non-Executive Chairman and two additional non-executive directors.

by tickstock newsroom
The image depicts a man in a dark suit walking away down a long, bright corporate corridor, viewed from behind. He carries a leather document wallet in one hand while the boardroom in the background is populated with directors seated around a table, engaged in discussion, their features softly blurred due to a shallow depth of field. aiImage created using AI — nano_banana_2

Genedrive (AIM:GDR) confirmed on 1 July that Dr. Ian Gilham has stepped down as Chairman, the latest move in a board restructuring process first announced on 26 May.

The AIM-listed company, which develops rapid pharmacogenetic tests used at the point of care, is actively recruiting a new independent Non-Executive Chairman alongside two independent Non-Executive Directors, with no timeline yet disclosed.

Chris Yates remains on the board as an independent Non-Executive Director in the interim, a position confirmed in the original May announcement.

CEO Gino Miele thanked Gilham for "the invaluable contributions he has made over many years in helping to shape the Company and its mission to transform patient outcomes through rapid pharmacogenetic testing."

by tickstock newsroom
"What does this mean for the sector?"
Ask TickstockIntelligent answers with real knowledgeTRY IN THE APP →

Related Stories